Literature DB >> 2903500

neu protooncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation.

J G Flanagan1, P Leder.   

Abstract

The protein encoded by the neu protooncogene (human gene symbol NGL for neuro/glioblastoma-derived) is a member of the surface receptor/tyrosine kinase family. Though its structure suggests that it can transduce a transmembrane signal, neither its extracellular ligand nor its critical intracellular substrates are known. To explore the functional properties of the protein encoded by neu, we created a fusion gene that joins the cytoplasmic domain of neu to the extracellular portion of an immunoglobulin heavy chain. The localization of the fusion polypeptide can then be controlled by coexpression with immunoglobulin light chain. In the absence of light chain, the heavy chain-neu polypeptide is expressed intracellularly and has no transforming activity. By contrast, in the presence of light chain the fusion polypeptide is expressed at the cell surface and produces tumorigenic foci. Thus, transformation apparently requires expression at the cell surface, where the neu intracellular domain can interact with components that are localized to the plasma membrane. The fusion protein is active in cellular transformation when the transmembrane domain is derived either from neu or from immunoglobulin, indicating that the neu transmembrane domain is not specifically required for transformation, although neu activation in tumors is known to result from a point mutation in this region. The extracellular immunoglobulin heavy and light chain domains of the fusion protein form a functional binding site that allows antigen to modulate its activity, reversing the transforming effect.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2903500      PMCID: PMC282353          DOI: 10.1073/pnas.85.21.8057

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Transformation of mammalian cells with genes from procaryotes and eucaryotes.

Authors:  M Wigler; R Sweet; G K Sim; B Wold; A Pellicer; E Lacy; T Maniatis; S Silverstein; R Axel
Journal:  Cell       Date:  1979-04       Impact factor: 41.582

Review 2.  Receptors for epidermal growth factor and other polypeptide mitogens.

Authors:  G Carpenter
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

3.  Synthesis of immunoglobulin mu chain gene products precedes synthesis of light chains during B-lymphocyte development.

Authors:  E Siden; F W Alt; L Shinefeld; V Sato; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

4.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

Authors:  P J Southern; P Berg
Journal:  J Mol Appl Genet       Date:  1982

5.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes.

Authors:  H Land; L F Parada; R A Weinberg
Journal:  Nature       Date:  1983 Aug 18-24       Impact factor: 49.962

6.  Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences.

Authors:  J Downward; Y Yarden; E Mayes; G Scrace; N Totty; P Stockwell; A Ullrich; J Schlessinger; M D Waterfield
Journal:  Nature       Date:  1984 Feb 9-15       Impact factor: 49.962

7.  Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies.

Authors:  A B Schreiber; T A Libermann; I Lax; Y Yarden; J Schlessinger
Journal:  J Biol Chem       Date:  1983-01-25       Impact factor: 5.157

8.  Induction of clonally restricted thymus-dependent antibody responses in vitro using phosphorylcholine derivatized sheep erythrocytes.

Authors:  J C Cambier; M J Neale
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

9.  Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells.

Authors:  T Kawamoto; J Mendelsohn; A Le; G H Sato; C S Lazar; G N Gill
Journal:  J Biol Chem       Date:  1984-06-25       Impact factor: 5.157

10.  Nucleic acid and protein sequences of phosphocholine-binding light chains.

Authors:  S P Kwan; S Rudikoff; J G Seidman; P Leder; M D Scharff
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

View more
  3 in total

1.  Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.

Authors:  S K Muthuswamy; M Gilman; J S Brugge
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

Review 2.  Cancer therapeutic antibodies come of age: targeting minimal residual disease.

Authors:  Tsipi Ben-Kasus; Bilha Schechter; Michael Sela; Yosef Yarden
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

3.  Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth.

Authors:  Georg Mahlknecht; Ruth Maron; Maicol Mancini; Bilha Schechter; Michael Sela; Yosef Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.